Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PCANTAG
Stock Latest News
Private Companies
Early Clinical Data On GIPR Antagonist Signals Pipeline Progress At Antag Therapeutics
18d ago
ANTAG
Premium
Private Companies
Antag Therapeutics Highlights Phase 2 Obesity Drug Development and Scientific Engagement
23d ago
ANTAG
Premium
Private Companies
Antag Therapeutics Strengthens Clinical Leadership With New Chief Medical Officer
2M ago
ANTAG
Premium
Private Companies
Antag Therapeutics – Weekly Recap
2M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Starts Phase 2a Trial of GIPR Antagonist AT7687 in Obesity and Type 2 Diabetes
2M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Advances Phase 2a Obesity and Diabetes Combination Trial
2M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Bolsters Leadership and Advances Lead Obesity Drug AT7687 Toward Phase 2
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Strengthens Board Leadership as AT7687 Advances to Phase 2
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Names Industry Veteran Keith Leonard as Chairman to Steer Phase 2 Obesity Program
4M ago
ANTAG
Premium
Private Companies
Early-Stage Metabolic Program Advances Toward Phase 2a at Antag Therapeutics
4M ago
ANTAG
Premium
Private Companies
Early-Stage GIPR Antagonist Data Positions Antag Therapeutics in Obesity and Diabetes Pipeline
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Advances AT7687 After Positive Phase 1 Data and New Obesity Combination Results
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Elevates Obesity Candidate AT7687 at Key Cardiometabolic Forum
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Highlights AT7687 at Obesity and Cardiometabolic Innovation Forum
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Highlights AT7687 at Obesity and Cardiometabolic Innovation Forum
4M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Appoints Veteran Metabolic R&D Leader as CEO Ahead of Key Phase 2a Obesity Trial
5M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Names New CEO as Lead Obesity Candidate Advances Toward Phase 2a
5M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Installs New CEO as Lead Obesity Drug Advances Toward Phase 2a
5M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Brings New CEO as Lead Obesity Candidate Advances to Phase 2a
5M ago
ANTAG
Premium
Private Companies
Antag Therapeutics Showcases First-in-Human AT7687 Data Ahead of Phase 2 Obesity Trials
6M ago
ANTAG
Premium
Private Companies
Antag Therapeutics to Present AT7687 Data at 2026 ADA Scientific Sessions
6M ago
ANTAG
Premium
Private Companies
Antag Therapeutics to Unveil First-in-Human AT7687 Data as It Prepares Phase 2 Obesity Studies
6M ago
ANTAG
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
